Weekly Ards Research Analysis
This week’s ARDS literature highlights mechanistic discoveries linking inflammation to regulated cell death and drug resistance, immunometabolic drivers in macrophages, and pragmatic clinical tools for early risk stratification. High-impact preclinical work nominates SERPINE1 as a ferroptosis hub and shows inflammation-driven GLP‑1R epigenetic silencing that can be reversed to restore therapeutic responses. Concurrent clinical/technical studies support biomarker-driven triage (sRAGE, FI‑Lab), EC
Summary
This week’s ARDS literature highlights mechanistic discoveries linking inflammation to regulated cell death and drug resistance, immunometabolic drivers in macrophages, and pragmatic clinical tools for early risk stratification. High-impact preclinical work nominates SERPINE1 as a ferroptosis hub and shows inflammation-driven GLP‑1R epigenetic silencing that can be reversed to restore therapeutic responses. Concurrent clinical/technical studies support biomarker-driven triage (sRAGE, FI‑Lab), ECMO/ventilation configuration optimization, and deployment-ready AI models for earlier ARDS diagnosis and prognosis.
Selected Articles
1. SERPINE1 drives ferroptosis in acute respiratory distress syndrome by disrupting mitochondrial NAD
Multi-system experiments (human samples, LPS mouse models, AT2 cells) identify SERPINE1 as an upstream driver that perturbs mitochondrial NAD/NADH balance, impairs Sirt3 activity, and promotes ferroptosis in ARDS; genetic or pharmacologic SERPINE1 inhibition reduced lung injury and restored antioxidant/iron-handling pathways.
Impact: Uncovers a novel SERPINE1–NAD/NADH–Sirt3 axis that mechanistically links inflammation to ferroptosis, nominating a druggable node with in vivo efficacy signals.
Clinical Implications: Provides a rationale to test SERPINE1 inhibitors or mitochondrial redox modulators in translational ARDS models and early-phase trials, and to define SERPINE1-high endotypes for predictive enrichment.
Key Findings
- SERPINE1 upregulated in ARDS patient samples, LPS mouse lungs, and LPS-treated AT2 cells and correlated with severity.
- SERPINE1 loss or pharmacologic inhibition reduced ferroptosis markers (ACSL4, ALOX12), restored SLC7A11/GPX4/FTH1, and attenuated lung injury.
- Mechanistically, SERPINE1 perturbs mitochondrial NAD/NADH balance and Sirt3 activity via interaction with complex I subunits (e.g., NDUFB10).
2. Inflammation-induced promoter hypermethylation of GLP-1R limits the protective effect of GLP-1R agonists against acute lung injury.
Preclinical work shows LPS/ALI upregulate DNMT3A/3B, hypermethylating the GLP‑1R promoter, decreasing chromatin accessibility and silencing receptor transcription across endothelial and epithelial lung cells. Genetic restoration of GLP‑1R (lentiviral/AAV) re‑sensitized tissues and outperformed GLP‑1R agonist monotherapy in vivo, reframing strategies toward receptor re‑sensitization.
Impact: Identifies an epigenetic mechanism of therapeutic resistance to GLP‑1R agonists in ALI/ARDS and demonstrates a feasible genetic re‑sensitization strategy with in vivo benefit.
Clinical Implications: Suggests assessing GLP‑1R expression/methylation for patient selection and investigating epigenetic or gene‑based companion strategies to restore receptor expression before or alongside GLP‑1R agonists in translational trials.
Key Findings
- LPS and ALI reduce GLP‑1R expression in endothelial, bronchial, and alveolar epithelial cells and in ALI mouse lungs.
- DNMT3A/3B upregulation causes GLP‑1R promoter hypermethylation, decreased chromatin accessibility, and transcriptional silencing (ATAC‑seq, bisulfite sequencing).
- Lentiviral/AAV-mediated GLP‑1R restoration reinstated GLP‑1RA anti‑inflammatory effects and improved in vivo protection versus GLP‑1RA alone.
3. GPR161 contributes to macrophage glycolytic reprogramming via targeting C5aR1 in acute lung injury.
Human monocytes from ARDS patients show elevated GPR161 correlated with severity. Macrophage-specific and global GPR161 knockout attenuated lung inflammation in LPS- and sepsis-induced ALI models. Mechanistic data indicate GPR161 suppresses C5aR1 to drive glycolytic reprogramming and macrophage activation, positioning GPR161 as an immunometabolic target.
Impact: Identifies a novel immunometabolic axis (GPR161 → C5aR1) controlling macrophage glycolysis and inflammatory activation with convergent human, in vivo, and in vitro evidence.
Clinical Implications: Preclinical evidence supports exploration of GPR161 modulation or downstream metabolic interventions as macrophage‑directed therapies in ARDS and suggests circulating GPR161 expression could be evaluated as a stratification biomarker.
Key Findings
- Elevated GPR161 in circulating monocytes from ARDS patients correlates with severity.
- GPR161 knockout (global and macrophage‑specific) reduces lung inflammation in LPS- and sepsis-associated ALI models.
- GPR161 promotes macrophage glycolysis and activation by suppressing C5aR1 (RNA‑seq, co‑IP, surface plasmon resonance).